Immunic Has Received A Notice Of Allowance From United States Patent And Trademark Office For Patent Covering Composition-Of-Matter Of Vidofludimus Calcium (IMU-838) And Related Production Method, Expected To Provide Protection Into 2039
Portfolio Pulse from Benzinga Newsdesk
Immunic, Inc. has received a notice of allowance from the USPTO for a patent covering the composition-of-matter of Vidofludimus Calcium (IMU-838) and its production method, expected to extend protection into 2039.
March 20, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunic, Inc. has been granted a notice of allowance for a patent on IMU-838, securing its protection until 2039.
The granting of a patent notice of allowance by the USPTO for Immunic's IMU-838 is a significant positive development. It not only secures the company's intellectual property rights on the composition and production method of this promising treatment but also extends these protections into 2039. This could potentially safeguard revenue streams and market exclusivity for IMU-838 for an extended period, which is likely to be viewed positively by investors and could lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100